Drug
Vemurafenib
Data on this page refer exclusively to patients treated with
Vemurafenib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
BRAF inhibitor group page.
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | BRAF/MEK Pathway Inhibitors |
| Group | BRAF inhibitor |
| Mechanism of Action | BRAF inhibitor |
| Half-life | 52 h |
